Sahib Singh, Muhammad Asim Shabbir, Nidhish Tiwari, Kevin Bliden, Udaya S Tantry, Paul A Gurbel, Mohammed Y Kanjwal, Scott W Lundgren
{"title":"经导管边缘对边缘修复与手术治疗继发性二尖瓣反流的meta分析。","authors":"Sahib Singh, Muhammad Asim Shabbir, Nidhish Tiwari, Kevin Bliden, Udaya S Tantry, Paul A Gurbel, Mohammed Y Kanjwal, Scott W Lundgren","doi":"10.1016/j.carrev.2025.06.012","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Transcatheter edge-to-edge repair (TEER) in patients with secondary mitral regurgitation (MR) has shown variable outcomes in clinical studies when compared with mitral valve surgery. We conducted a meta-analysis to reconcile the data.</p><p><strong>Methods: </strong>Online databases were searched for studies assessing TEER vs surgery for secondary MR. The outcomes of interest were length of hospital stay, all deaths, heart failure (HF) rehospitalization, mitral valve reintervention, implantation of left ventricular assist device (LVAD), stroke and recurrence of grade 3 or 4 MR. Pooled odds ratios (OR) and standardized mean difference (SMD), with 95 % confidence intervals (CI) were calculated.</p><p><strong>Results: </strong>Eight studies (1 randomized and 7 observational) with a total of 1436 patients (TEER n = 826, surgery n = 610) were included. Length of hospital stay was shorter in the TEER group (SMD -2.50, 95 % CI -4.65 to -0.35, p = 0.02). No significant differences were found between the two groups with respect to all deaths (p = 0.80), HF rehospitalization, mitral valve reintervention, implantation of LVAD and stroke. Recurrence of grade 3 or 4 MR was higher in the TEER group (OR 5.33, 95 % CI 2.57 to 11.03, p < 0.00001).</p><p><strong>Conclusions: </strong>In patients with secondary MR, TEER and surgery have comparable outcomes such as mortality, except for the lower recurrence of grade 3 or 4 MR in the surgical group. Thus, TEER may be the first approach in such patients, except in low surgical risk cases who need other concomitant cardiac surgeries.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meta-analysis of transcatheter edge-to-edge repair vs surgery for secondary mitral regurgitation.\",\"authors\":\"Sahib Singh, Muhammad Asim Shabbir, Nidhish Tiwari, Kevin Bliden, Udaya S Tantry, Paul A Gurbel, Mohammed Y Kanjwal, Scott W Lundgren\",\"doi\":\"10.1016/j.carrev.2025.06.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Transcatheter edge-to-edge repair (TEER) in patients with secondary mitral regurgitation (MR) has shown variable outcomes in clinical studies when compared with mitral valve surgery. We conducted a meta-analysis to reconcile the data.</p><p><strong>Methods: </strong>Online databases were searched for studies assessing TEER vs surgery for secondary MR. The outcomes of interest were length of hospital stay, all deaths, heart failure (HF) rehospitalization, mitral valve reintervention, implantation of left ventricular assist device (LVAD), stroke and recurrence of grade 3 or 4 MR. Pooled odds ratios (OR) and standardized mean difference (SMD), with 95 % confidence intervals (CI) were calculated.</p><p><strong>Results: </strong>Eight studies (1 randomized and 7 observational) with a total of 1436 patients (TEER n = 826, surgery n = 610) were included. Length of hospital stay was shorter in the TEER group (SMD -2.50, 95 % CI -4.65 to -0.35, p = 0.02). No significant differences were found between the two groups with respect to all deaths (p = 0.80), HF rehospitalization, mitral valve reintervention, implantation of LVAD and stroke. Recurrence of grade 3 or 4 MR was higher in the TEER group (OR 5.33, 95 % CI 2.57 to 11.03, p < 0.00001).</p><p><strong>Conclusions: </strong>In patients with secondary MR, TEER and surgery have comparable outcomes such as mortality, except for the lower recurrence of grade 3 or 4 MR in the surgical group. Thus, TEER may be the first approach in such patients, except in low surgical risk cases who need other concomitant cardiac surgeries.</p>\",\"PeriodicalId\":47657,\"journal\":{\"name\":\"Cardiovascular Revascularization Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Revascularization Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.carrev.2025.06.012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.carrev.2025.06.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景:与二尖瓣手术相比,经导管边缘到边缘修复(TEER)在继发性二尖瓣反流(MR)患者中的临床研究显示出不同的结果。我们进行了荟萃分析来调和数据。方法:检索在线数据库,评估TEER与手术治疗继发性mr的研究,关注的结果是住院时间、所有死亡、心力衰竭(HF)再住院、二尖瓣再介入、左心室辅助装置(LVAD)植入、卒中和3级或4级mr复发,计算合并优势比(or)和标准化平均差(SMD), 95%置信区间(CI)。结果:纳入8项研究(1项随机研究,7项观察研究),共1436例患者(TEER n = 826,手术n = 610)。TEER组住院时间较短(SMD -2.50, 95% CI -4.65 ~ -0.35, p = 0.02)。两组患者在所有死亡(p = 0.80)、HF再住院、二尖瓣再介入、LVAD植入和卒中方面均无显著差异。3级或4级MR复发率在TEER组较高(or 5.33, 95% CI 2.57至11.03,p)。结论:在继发性MR患者中,TEER和手术具有相当的结果,如死亡率,除了手术组的3级或4级MR复发率较低。因此,除了需要其他心脏手术的低手术风险病例外,TEER可能是此类患者的首选方法。
Meta-analysis of transcatheter edge-to-edge repair vs surgery for secondary mitral regurgitation.
Background: Transcatheter edge-to-edge repair (TEER) in patients with secondary mitral regurgitation (MR) has shown variable outcomes in clinical studies when compared with mitral valve surgery. We conducted a meta-analysis to reconcile the data.
Methods: Online databases were searched for studies assessing TEER vs surgery for secondary MR. The outcomes of interest were length of hospital stay, all deaths, heart failure (HF) rehospitalization, mitral valve reintervention, implantation of left ventricular assist device (LVAD), stroke and recurrence of grade 3 or 4 MR. Pooled odds ratios (OR) and standardized mean difference (SMD), with 95 % confidence intervals (CI) were calculated.
Results: Eight studies (1 randomized and 7 observational) with a total of 1436 patients (TEER n = 826, surgery n = 610) were included. Length of hospital stay was shorter in the TEER group (SMD -2.50, 95 % CI -4.65 to -0.35, p = 0.02). No significant differences were found between the two groups with respect to all deaths (p = 0.80), HF rehospitalization, mitral valve reintervention, implantation of LVAD and stroke. Recurrence of grade 3 or 4 MR was higher in the TEER group (OR 5.33, 95 % CI 2.57 to 11.03, p < 0.00001).
Conclusions: In patients with secondary MR, TEER and surgery have comparable outcomes such as mortality, except for the lower recurrence of grade 3 or 4 MR in the surgical group. Thus, TEER may be the first approach in such patients, except in low surgical risk cases who need other concomitant cardiac surgeries.
期刊介绍:
Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.